Yojia Bio Participates in the Release of China's First Technical Specification for Nucleotide Sequence Design of Oligonucleotide Therapeutics

On May 11, the group standard "Small Nucleic Acid Drugs - Technical Regulations for Nucleotide Sequence Design" (T/CIET 1219—2025), led by the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences and jointly drafted with China's top scientific research institutions and leading enterprises in the industry, was officially released by the China International Economic and Technical Cooperation Promotion Association.Youjia (Hangzhou) Biomedical Technology Co., Ltd. was one of the main drafting organizations and participated throughout the development of this milestone national group standard.

The introduction of "Technical Regulations for the Design of Nucleotide Sequences in Small Nucleic Acid Drugs" fills the gap in technical standards in this field in China, providing a scientific and systematic guiding framework for the research and development of small nucleic acid drugs. It covers all key aspects, including preliminary preparation, design theory, sequence screening and optimization, functional verification, safety assessment, ethical regulations, and more.This is of great significance for enhancing the R&D level of small nucleic acid drugs in China, standardizing industry development, and accelerating the industrialization process.

YOUJIA BIO, with its profound technical accumulation and rich practical experience in the field of small nucleic acid drugs, particularly in siRNA sequence design and efficient delivery systems, has been deeply involved in the entire process of standard formulation. Dr. Zhao Chengjiang, the Chief Technology Officer (CTO) of the company, as one of the main drafters of this standard, has provided critical support and significant contributions to the scientific nature and practicality of the standard with his cutting-edge expertise and unique industry insights.

YOUJIA BIO has always been committed to innovation and breakthroughs in the field of small nucleic acid drugs. The participation in the formulation of national-level group standards alongside many high-level organizations this time not only represents the industry's high recognition of YOUJIA BIO’s technical strength but also exemplifies the company’s active commitment to industry responsibility and promotion of standardized industrial development.

In the future, YOUJIA BIO will continue to uphold a professional and rigorous attitude, guided by this group standard, continuously optimize and iterate its self-developed technology platforms, further enhancing the efficiency and accuracy of small nucleic acid drug sequence design. At the same time, we will deepen collaboration with academia and the industry, accelerate the clinical translation and industrial implementation of innovative drugs, providing more safe, effective, and accessible innovative therapies for patients in China and around the world, contributing to the high-quality development of China's biopharmaceuticals industry.